News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,057 Results
Type
Article (43374)
Company Profile (353)
Press Release (670330)
Section
Business (211572)
Career Advice (2079)
Deals (36341)
Drug Delivery (90)
Drug Development (82050)
Employer Resources (172)
FDA (16641)
Job Trends (15270)
News (355523)
Policy (33321)
Tag
Academia (2683)
Alliances (52113)
Alzheimer's disease (1251)
Approvals (16570)
Artificial intelligence (150)
Bankruptcy (357)
Best Places to Work (11829)
Biotechnology (252)
Breast cancer (122)
Cancer (1100)
Cardiovascular disease (98)
Career advice (1739)
Cell therapy (246)
Clinical research (65024)
Collaboration (404)
Compensation (199)
COVID-19 (2615)
C-suite (100)
Data (1135)
Diabetes (153)
Diagnostics (6405)
Earnings (86419)
Employer resources (151)
Events (114118)
Executive appointments (320)
FDA (17188)
Funding (365)
Gene therapy (187)
GLP-1 (593)
Government (4428)
Healthcare (19384)
Infectious disease (2702)
Inflammatory bowel disease (109)
Interviews (319)
IPO (16638)
Job creations (3813)
Job search strategy (1488)
Layoffs (425)
Legal (8076)
Lung cancer (173)
Manufacturing (180)
Medical device (13901)
Medtech (13906)
Mergers & acquisitions (19782)
Metabolic disorders (409)
Neuroscience (1531)
NextGen Class of 2024 (6831)
Non-profit (4601)
Northern California (1495)
Obesity (233)
Opinion (190)
Patents (108)
People (58483)
Phase I (20347)
Phase II (28620)
Phase III (21253)
Pipeline (457)
Postmarket research (2574)
Preclinical (8747)
Radiopharmaceuticals (254)
Rare diseases (224)
Real estate (6216)
Regulatory (22095)
Research institute (2450)
Resumes & cover letters (360)
Southern California (1320)
Startups (3827)
United States (13820)
Vaccines (578)
Weight loss (172)
Date
Today (137)
Last 7 days (780)
Last 30 days (3846)
Last 365 days (36667)
2024 (33625)
2023 (41135)
2022 (52398)
2021 (56996)
2020 (55618)
2019 (48411)
2018 (36446)
2017 (33542)
2016 (33145)
2015 (39364)
2014 (32946)
2013 (27994)
2012 (30251)
2011 (30854)
2010 (28815)
Location
Africa (754)
Arizona (201)
Asia (39777)
Australia (6609)
California (3387)
Canada (1296)
China (253)
Colorado (150)
Connecticut (158)
Europe (86879)
Florida (462)
Georgia (124)
Illinois (361)
Indiana (202)
Kansas (99)
Maryland (588)
Massachusetts (2685)
Michigan (173)
Minnesota (280)
New Jersey (972)
New York (967)
North Carolina (743)
Northern California (1495)
Ohio (141)
Pennsylvania (853)
South America (1149)
Southern California (1320)
Texas (472)
Utah (94)
Washington State (372)
714,057 Results for "retractable technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Retractable Technologies, Inc. Reports Results for 2023
Retractable Technologies, Inc. reports the following information relating to the year ended December 31, 2023.
March 29, 2024
·
4 min read
Business
Retractable Technologies, Inc. Results for the Period Ended March 31, 2024
Retractable Technologies, Inc. (NYSE American: RVP) reports total net sales of $7.6 million for the first three months of 2024 and an operating loss of nearly $3.0 million for the period, as compared to total net sales for the same period last year of $11.0 million and an operating loss of $2.7 million.
May 15, 2024
·
5 min read
Policy
Retractable Technologies, Inc. Not Impacted by FDA Safety Communication
Retractable Technologies, Inc. reports that the FDA Safety Communication “Evaluating Plastic Syringes Made in China for Potential Device Failures” on November 30, 2023 does not refer to syringes from Retractable Technologies Inc.
December 1, 2023
·
2 min read
Lone Star Bio
Retractable Technologies, Inc. Results for the Periods Ended September 30, 2023
Retractable Technologies, Inc. reports that its loss from operations was $8.7 million for the first nine months of 2023 and that it had an operating loss of $936 thousand for the third quarter of 2023, as compared to an operating income for the same periods last year of $7.0 million for the first nine months of 2022 and an operating loss of $691 thousand for the third quarter of 2022.
November 14, 2023
·
7 min read
Business
Retractable Technologies, Inc. Results for the Period Ended June 30, 2023
Retractable Technologies, Inc. reports total net sales of $8.0 million for the second quarter of 2023 and an operating loss of $5.0 million for the second quarter, as compared to total net sales for the same quarter last year of $14.3 million and an operating loss of $2.1 million.
August 14, 2023
·
6 min read
Business
Retractable Technologies, Inc. Reports Results For 2022
Retractable Technologies, Inc. reports the following information relating to the year ended December 31, 2022.
March 30, 2023
·
4 min read
Lone Star Bio
Retractable Technologies, Inc. Results for the Period Ended March 31, 2023
Retractable Technologies, Inc. reports total net sales of $11.0 million for the first three months of 2023 and an operating loss of $2.7 million for the period, as compared to total net sales for the same period last year of $44.7 million and an operating income of $9.7 million.
May 15, 2023
·
5 min read
Psychedelics
MDMA Papers Retracted for ‘Unethical Conduct’ on Heels of Lykos’ FDA Rejection
A day after the regulator denied approval of Lykos’ MDMA-assisted PTSD therapy, a medical journal pulled three studies related to the use of the psychedelic in the indication.
August 12, 2024
·
2 min read
·
Tristan Manalac
Genetown
Microline Surgical Expands Healthcare Products Offering with Acquisition of Surgical Instrumentation Assets from Retraction Limited
Microline Surgical, Inc., a subsidiary of HOYA Corporation, announced that it has acquired the rights to certain laparoscopic instrumentation assets from RETRACTION Limited.
November 22, 2023
·
3 min read
Lone Star Bio
Retractable Technologies, Inc. Reports Private Stock Repurchase
Retractable Technologies, Inc. announces that it has agreed to repurchase three million shares of its common stock in a private transaction with BML Investment Partners, L.P. Braden M. Leonard, on behalf of the selling shareholder, approached the Company with an offer to sell a block of shares prior to year-end.
December 29, 2022
·
2 min read
1 of 71,406
Next